1Fitzpatrick AL,Kuller LH,Ives DG,et al.Incidence and prevalence of dementia in the Cardiovascular Health Study[J].J Am Geriatr Soc,2004 ;52:195-204.
2Fratiglioni L,De Ronchi D,Aguero-Torres H.Worldwide prevalence and incidence of dementia[J].Drugs Aging,1999; 15:365-75.
3Minino AM,Arias E,Kochanek KD,et al.Deaths:final data for 2000[J].Natl Vital Stat Rep,2002 ;50:1-119.
4Knopman DS,KeKoshy ST,Cummings JL,et al.Practice parameter:diagnosis of dementia (an evidence-based review).Report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neurology,2001 ;56:1143-53.
5Flirski M,Sobow T.Biochemical markers and risk factors of Alzheimer's disease[J].Curr Alzheimer Res,2005 ;2 (1):47-64.
6Maccioni RB,Lavados M,Guillon MK,et al.Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects[J].Neurobiol Aging,2006;27(2):237-44.
7Hyman BT,Trojanowski JQ.Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease[J].Neuropathol Exp,1997 ;56:1095-7.
8Squitti R,Barbati G,Rossi L,et al.Excess of nonceruloplasmin serum copper in AD correlates with MMSE,CSF[beta] -amyloid,and h-tau[J].Neurology,2006 ;67 (1):76-82.
9Andreasen N,Sjogren M,Blennow K.CSF markers for Alzheimer's disease:total tau,phosphos-tau and Abeta42[J].World Biol Psychiatry,2003 ;4(4):147-55.
10Sjogren M,Vanderstichele H,Agren H,et al.Tau and Abeta42 in cerebrospinal fluid from healthy adults 21 -93 years of age:establishment of reference values[J].Clin Chem,2001 ;47:1776-81.
8Nasreddine ZS,Phillips NA,Bedirian V,et al.The Montreal Cognitive Assessment,MoCA:a brief screening tool for mild cognitive impairment[J].J Am Geriatr Soc,2005;53(4):695-9.
9Feldman HH,Lane R.Study 304 Group.Rivastigmine:a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer′s disease[J].J Neurol Neurosurg Psychiatry,2007;78(10):1056-63.
10Alvarez XA,Cacabelos R,Laredo M,et al.A 24-week,double-blind,placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer′s disease[J].Eur J Neurol,2006;13(1):43-54.
